T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Posted ContentDOI
Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error corrected circulating tumour DNA sequencing
Sonia Mansukhani,Louise J. Barber,Sing Yu Moorcraft,Michael Davidson,Andrew Woolston,Beatrice Griffiths,Kerry Fenwick,Bram Herman,Nik Matthews,Ben O'Leary,Sanna Hulkki,David Gonzalez De Castro,Mike Hubank,Anisha Patel,Andrew Wotherspoon,Aleruchi Okachi,Isma Rana,Ruwaida Begum,Matthew N. Davies,Matthew N. Davies,Thomas Powles,Katharina von Loga,Nicholas C. Turner,Nicholas C. Turner,David Watkins,Ian Chau,David Cunningham,Naureen Starling,Marco Gerlinger,Marco Gerlinger +29 more
TL;DR: A targeted cfDNA sequencing technology using novel off-the-shelf molecular barcodes for error correction, in combination with custom solution hybrid capture enrichment, enables broad insights into cancer genomes and evolution.
Journal ArticleDOI
A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).
Toni K. Choueiri,Elizabeth R. Plimack,Hendrik-Tobias Arkenau,Eric Jonasch,Daniel Y.C. Heng,Thomas Powles,Melanie M. Frigault,Edwin Clark,Amir Handzel,Humphrey Gardner,Shethah Morgan,Laurence Albiges,Sumanta K. Pal +12 more
TL;DR: This study evaluates savolitinib in PRCC patients dosed at 600mg daily until disease progression, finding that ORR is the primary endpoint and PFS & DoR are secondary endpoints.
Proceedings ArticleDOI
Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer
Arjun Vasant Balar,Amit Mahipal,Enrique Grande,Victor M. Villalobos,Sébastien Salas,Taek Won Kang,Se Hyun Kim,Thomas Powles,Frank Tsai,Aung Naing,Albiruni Ryan Abdul Razak,Yohann Loriot,Ji Youl Lee,Sang Joon Shin,Rafael Morales-Barrera,Natasha Angra,Feng Xiao,Shaad Essa Abdullah,Michiel S. van der Heijden +18 more
TL;DR: D+T had a manageable safety profile and encouraging antitumor activity and survival rate in previously treated mUC regardless of PD-L1 status, but patients with either tumor or immune cell expression ≥25% had numerically higher response rates and 6-month OS rates than those with Conclusions: D+.
Journal ArticleDOI
Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity
Joaquim Bellmunt,Francesc Pons,Abigail Foreshew,André P. Fay,Thomas Powles,Camillo Porta,Sergio Bracarda,Megan E. Lampron,Linda Cerbone,Cora N. Sternberg,Thomas E. Hutson,Toni K. Choueiri +11 more
TL;DR: In this retrospective study, targeting VEGF was an effective strategy after disease progression during pazopanib treatment, although OS was not different among patients treated with V EGF or mTORi.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
R. Kanesvaran,Camillo Porta,A. Wong,Thomas Powles,Q.S. Ng,Manuela Schmidinger,Dingwei Ye,H. Malhotra,Y. Miura,J.-L. Lee,F.L.T. Chong,Yeong-Shiau Pu,C.-C. Yen,M. Saad,H.J. Lee,H. Kitamura,G.S. Bhattacharyya,Giuseppe Curigliano,E. Poon,S.P. Choo,Solange Peters,E. Lim,T. Yoshino,G. Pentheroudakis +23 more
TL;DR: The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of renal cell carcinoma was published in 2019 with an update planned for 2021 as mentioned in this paper.